Stocks
Arrowhead Pharmaceuticals (ARWR) EBITDA US GAAP (year values) |
|||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | CAGR 5 years ? | |||
| EBITDA, bln rub | ? | 65.6 | -87.2 | -140.8 | -178.5 | -188.2 | -445.5 | ||
| Changes by years, y/y, % | -227% | -233% | +61% | +27% | +5% | +29.5% | |||
Arrowhead Pharmaceuticals. EBITDA US GAAP, bln rub
Arrowhead Pharmaceuticals. EBITDA US GAAP, changes, %
Arrowhead Pharmaceuticals. EBITDA US GAAP, sum by quarters, bln rub
Arrowhead Pharmaceuticals (ARWR) EBITDA US GAAP (quarter values) |
||||||||
| 2023Q2 | 2023Q3 | 2023Q4 | 2024Q1 | 2024Q2 | LTM ? | |||
| EBITDA, bln rub | ? | 55.4 | -94.9 | -99.9 | -129.1 | -121.7 | -445.5 | |
| Changes by years, y/y, % | +25% | +35% | +19% | +206% | -320% | |||
| Changes by quarters, q/q, % | -231% | -271% | +5% | +29% | -6% | |||
